A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant
Treatment of Overweight and Obese Women with Early Breast Cancer

Learn more about the Breast Cancer WEight Loss Study (BWEL Study) or contact the Pottstown Hospital Clinical Research office at 610-327-7544.

A191901: The GET SET Study (Phase III, Randomized, Therapeutic Trial)

Eligibility: Stg I-III, Hormone Receptor-positive, HER2-Negative breast cancer who have completed chemo/radiation/surgery and recently started or will start Endocrine Therapy (ie. Anastrozole, Tamoxifen, Exemestane, Letrozole etc).

The purpose of this study is to help patients improve endocrine therapy compliance, and assess the best method of improving endocrine therapy compliance (text message reminder, motivational interviewing counseling, a combination of both or enhanced usual care)

Learn more about the A191901 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.

A221602: (Phase III, Randomized, Double Blind, Placebo Controlled Therapeutic Trial)

Eligibility: Diagnosis of Cancer Stage I-IV. No prior treatment with chemotherapy. Scheduled to receive ether regimen of Cisplatin or Adriamycin/Cytoxan.

The purpose of this to compare the proportion of patients with no nausea for the acute, delayed and overall time periods for patients receiving highly emetogenic chemotherapy using Olanzapine (Zyprexa) with or without Fosaprepitant (Emend).

Learn more about the A221602 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.

Alliance-A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib.

The purpose of this study is to compare the usual treatment with T-DM1 alone to T-DM1 plus tucatinib.

Learn more about the Alliance-A011801 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Alliance- A221505: A randomized trial of hypofractionated post-mastectomy radiation with breast reconstruction.

The purpose of this study is to determine whether a short course radiation therapy option (3 to 4 weeks) after mastectomy is as safe and effective in the setting of breast reconstruction as the usual 5-to-6-week treatment course.

Learn more about the Alliance- A221505 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Daiichi Sankyo, Inc. / Destiny-05/NSABP B-60: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Subjects with High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy.

The purpose of this study is to determine if T-DXd would be effective in the treatment of HER2-positive early breast cancer in subjects that have already had treatment prior to breast cancer surgery, specifically for subjects that are considered at high risk for their breast cancer to return.

Learn more about the Destiny-05/NSABP B-60 trial or call the Reading Hospital Protocol Office at 484-628-8193.

ECOG/ACRIN-EA1181: (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response.

The purpose of this study is to test whether it is safe to eliminate additional chemotherapy after surgery in patients with HER2-positive breast cancer who have no remaining cancer at surgery, after receiving a single chemotherapy drug (for most patients, paclitaxel), with Herceptin (trastuzumab) and Perjeta (pertuzumab) for 12 weeks before surgery.

Learn more about the ECOG/ACRIN-EA1181 trial or call the Reading Hospital Protocol Office at 484-628-8193.

Johns Hopkins-J15212: Phase II Trial of Palbociclib with Fulvestrant in individuals with hormone receptor-positive, HER2-negative metastatic breast cancer who have progressed on treatment with Palbociclib and an aromatase inhibitor.

The purpose of this study is to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy after disease progression.

Learn more about the Johns Hopkins- J15212 trial or call the Reading Hospital Protocol office at 484-628-8193.

NRG- BR004: A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast

The purpose of this study is to compare the usual treatment plus placebo to the usual treatment plus atezolizumab.

Learn more about the NRG- BR004 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-BR005: This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II- IIIA breast cancer undergoing breast-conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may also be compared to the tumor removed during surgery to check if they are the same.

The purpose of this study is to look at tumor tissue collected from a biopsy done before breast surgery to check if the chemotherapy that patients received destroyed their breast cancer cells.

Learn more about the NRG- BR005 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node-Positive Breast Cancer

The purpose of this study is to compare any good and bad effects of not giving regional radiotherapy to using regional radiotherapy.

Learn more about the NRG-CCTG MA.39 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-BR003: A randomized Phase III trial of adjuvant therapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple-negative invasive breast cancer.

The purpose of this study is to compare the good and bad effects of the chemotherapy drug carboplatin given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.

Learn more about the NRG-BR003 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NSABP-B51/RTOG 1304: A randomized phase III clinical trial evaluating post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy

The purpose of this clinical trial is to study women who have cancer cells in their lymph nodes at the time that the breast cancer is diagnosed and then have chemotherapy before surgery that clears the cancer cells from the lymph nodes. Following surgery, radiation to the breast and lymph nodes will be evaluated against radiation to the breast only.

Learn more about the NSABP-B51/RTOG 1304 trial or call the Reading Hospital Protocol Office at 484-628-8193.

SWOG-S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with > 1cm residual invasive cancer or positive lymph nodes (YPN+) after neoadjuvant

The purpose of this study is to compare the usual approach (i.e., no more treatment or additional post-operative chemotherapy), to any effects, good and/or bad, of the experimental drug MK-3475 (also called pembrolizumab) after surgery.

Learn more about the trial SWOG-S1418/BR006 trial or call the Reading Hospital Protocol Office at 484-628-8193.

S1714: Neuropathy Trial (Observational Study)

Eligibility: Stg I,II or III primary non-small cell lung cancer, breast cancer or ovarian/fallopian tube cancer. Scheduled to receive taxane-based chemotherapy.

To develop and validate a prediction model of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.

Learn more about the S1714 trail or call the Phoenixville Hospital Clinical Research Office at 610-983-1811.

CK-SAPBI: CyberKnife Stereotactic Accelerated Partial Breast Irradiation Registry

Learn about the CK-SAPBI trail or contact the Pottstown Hospital Clinical Research office at 610-327-7544.